Skip to search boxSkip to navigationSkip to main content

Beyond metabolism: sexual dysfunction and weight-loss drugs

  • Jenyfer M. Fuentes-Mendoza
    ,
  • Marcio J. Concepción-Zavaleta(corresponding author)
    ,
  • Jeny J. Mendoza-Godoy
    ,
  • Luis Concepción-Urteaga
    ,
  • José Paz-Ibarra
    ,
  • Julia C. Coronado-Arroyo
*Corresponding author for this work
  • Universidad Científica del Sur
    ,
  • ,
  • Universidad Privada de Huancayo Franklin Roosevelt
    ,
  • Universidad Nacional de Trujillo
    ,
  • Hospital Nacional Edgardo Rebagliati Martins, EsSalud
    ,
  • Universidad Nacional Mayor de San Marcos
Research Output:
Contribution to journal
Review article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Article number

qeaf074

Journal (Volume, Issue Number)

Sexual medicine reviews (Volume 14, Issue 1)

Publication milestones

  • Published - 01/01/2026

Publication status

Published - 01/01/2026

ISSN

2050-0513

Publication IDs

  • Scopus: 105026689315
  • PubMed: 41427954

Abstract

Introduction Sexual dysfunction (SD) is a frequent and underrecognized complication of obesity, mediated by a complex interplay of hormonal, vascular, metabolic, and psychosocial pathways. Despite the established link between weight reduction and improved sexual health, the specific effects of new pharmacological weight-loss therapies on sexual function remain underexplored. Objectives To critically evaluate the recent evidence on the impact of weight-loss medications on sexual function, synthesizing clinical outcomes, mechanistic insights, and identifying critical research gaps. Methods We conducted an update and comprehensive narrative review using PubMed, Scopus and Embase databases. A systematic search strategy employed predefined terms related to obesity, SD, and pharmacotherapy. Eligible studies were those reporting sexual outcomes using validated instruments [eg, Female Sexual Function Index (FSFI), International Index of Erectile Function (IIEF)] or relevant clinical reports. Results GLP-1 receptor agonists show promising results in men, improving erectile function, testosterone levels, and sperm parameters. In contrast, direct evidence in women remains limited. Tirzepatide achieves unprecedented weight loss, but case reports suggest potential sexual side effects. Naltrexone/bupropion may benefit sexual desire through mood improvement, while phentermine/topiramate primarily enhances psychological well-being. Setmelanotide demonstrates the direct involvement of the melanocortin pathway in sexual function. Across all drug classes, sexual endpoints were typically secondary outcomes in clinical trials. Conclusion Pharmacological weight-loss therapies influence sexual health through multiple direct and indirect pathways. However, current evidence is inconsistent, and sex-specific data are scarce. Future clinical trials should systematically include validated sexual function measures as primary endpoints and stratify results by sex and comorbidities to better guide clinical practice in sexual medicine.

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
1
Mentions
1

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well